Author: "Jacobs, B. C." / Search Limiters: Full Text - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Jacobs, B. C."' showing total 121 results

Start Over Author "Jacobs, B. C." Search Limiters Full Text

121 results on '"Jacobs, B. C."'

1. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study

Author: Arends, S, Drenthen, J, de Koning, L, van den Bergh, P, Hadden, R, Kuwabara, S, Reisin, R, Shahrizaila, N, Ajroud-Driss, S, Antonini, G, Attarian, S, Balducci, C, Bertorini, T, Brannagan, T, Cavaletti, G, Chao, C, Chavada, G, Dillmann, K, Dimachkie, M, Galassi, G, Gutierrez-Gutierrez, G, Harbo, T, Islam, B, Islam, Z, Katzberg, H, Kusunoki, S, Manganelli, F, Miller, J, Pardo, J, Pereon, Y, Rajabally, Y, Sindrup, S, Stettner, M, Uncini, A, Verhamme, C, Vytopil, M, Waheed, W, Jacobs, B, Cornblath, D, Addington, J, Badrising, U, Barroso, F, Bateman, K, Bella, I, Benedetti, L, van den Berg, B, Bhavaraju-Sanka, R, Briani, C, Buermann, J, Busby, M, Butterworth, S, Casasnovas, C, Chen, S, Claeys, K, Conti, E, Cosgrove, J, Dalakas, M, van Damme, P, Dardiotis, E, Davidson, A, Doets, A, van Doorn, P, Echaniz-Laguna, A, Eftimov, F, Faber, K, Fazio, R, Feasby, T, Fehmi, J, Fokke, C, Fujioka, T, Fulgenzi, E, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, J, Goldstein, J, Gorson, K, Goyal, N, Granit, V, Gutmann, L, Hartung, H, Holt, J, Hsieh, S, Htut, M, Hughes, R, Jerico-Pascual, I, Kaida, K, Karafiath, S, Khoshnoodi, M, Kiers, L, Kleiweg, R, Kokubun, N, Kolb, N, van Koningsveld, R, van der Kooi, A, Kramers, H, Kuitwaard, K, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Lehmann, H, Cejas, L, Leonhard, S, Luijten, L, Lunn, M, Manji, H, Marfia, G, Infante, C, Martin-Aguilar, L, Martinez-Hernandez, E, Mataluni, G, Mattiazzi, M, Mcdermott, C, Meekins, G, Mohammad, Q, Monges, S, de la Tassa, G, Nascimbene, C, Nobile-Orazio, E, Nowak, R, Osei-Bonsu, M, Pelouto, F, Pulley, M, Gutierrez, L, Reddel, S, van der Ree, T, Rinaldi, S, Ripellino, P, Roberts, R, Rojas-Marcos, I, Roodbol, J, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Schenone, A, Tous, M, Sheikh, K, Silvestri, N, Sundrup, S, Sommer, C, Stein, B, Stino, A, Thomma, R, Twydell, P, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Walgaard, C, Wang, Y, Willison, H, Wirtz, P, van Woerkom, M, Zivkovic, S, Arends S., Drenthen J., de Koning L., van den Bergh P., Hadden R. D. M., Kuwabara S., Reisin R. C., Shahrizaila N., Ajroud-Driss S., Antonini G., Attarian S., Balducci C., Bertorini T., Brannagan T. H., Cavaletti G., Chao C. -C., Chavada G., Dillmann K. -U., Dimachkie M. M., Galassi G., Gutierrez-Gutierrez G., Harbo T., Islam B., Islam Z., Katzberg H., Kusunoki S., Manganelli F., Miller J. A. L., Pardo J., Pereon Y., Rajabally Y. A., Sindrup S., Stettner M., Uncini A., Verhamme C., Vytopil M., Waheed W., Jacobs B. C., Cornblath D. R., Addington J. M., Badrising U. A., Barroso F. A., Bateman K., Bella I., Benedetti L., van den Berg B., Bhavaraju-Sanka R., Briani C., Buermann J., Busby M., Butterworth S., Casasnovas C., Chen S., Claeys K., Conti E., Cosgrove J. S., Dalakas M., van Damme P., Dardiotis E., Davidson A., Doets A., van Doorn P., Echaniz-Laguna A., Eftimov F., Faber K. G., Fazio R., Feasby T. E., Fehmi J., Fokke C., Fujioka T., Fulgenzi E., Garssen M. P. J., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Goldstein J. M., Gorson K. C., Goyal N., Granit V., Gutmann L., Hartung H. -P., Holt J. K. L., Hsieh S. -T., Htut M., Hughes R. A. C., Jerico-Pascual I., Kaida K., Karafiath S., Khoshnoodi M. A., Kiers L., Kleiweg R. P., Kokubun N., Kolb N. A., van Koningsveld R., van der Kooi A. J., Kramers H., Kuitwaard K., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V. H., Lehmann H., Cejas L. L., Leonhard S. E., Luijten L., Lunn M. P. T., Manji H., Marfia G. A., Infante C. M., Martin-Aguilar L., Martinez-Hernandez E., Mataluni G., Mattiazzi M., McDermott C., Meekins G., Mohammad Q. D., Monges S., de la Tassa G. M., Nascimbene C., Nobile-Orazio E., Nowak R. J., Osei-Bonsu M., Pelouto F., Pulley M. T., Gutierrez L. Q., Reddel S. W., van der Ree T., Rinaldi S., Ripellino P., Roberts R. C., Rojas-Marcos I., Roodbol J., Rudnicki S. A., Sachs G. M., Samijn J. P. A., Santoro L., Schenone A., Tous M. J. S., Sheikh K. A., Silvestri N. J., Sundrup S. H., Sommer C., Stein B., Stino A. M., Thomma R. C. M., Twydell P., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Walgaard C., Wang Y., Willison H. J., Wirtz P. W., van Woerkom M., Zivkovic S. A., Arends, S, Drenthen, J, de Koning, L, van den Bergh, P, Hadden, R, Kuwabara, S, Reisin, R, Shahrizaila, N, Ajroud-Driss, S, Antonini, G, Attarian, S, Balducci, C, Bertorini, T, Brannagan, T, Cavaletti, G, Chao, C, Chavada, G, Dillmann, K, Dimachkie, M, Galassi, G, Gutierrez-Gutierrez, G, Harbo, T, Islam, B, Islam, Z, Katzberg, H, Kusunoki, S, Manganelli, F, Miller, J, Pardo, J, Pereon, Y, Rajabally, Y, Sindrup, S, Stettner, M, Uncini, A, Verhamme, C, Vytopil, M, Waheed, W, Jacobs, B, Cornblath, D, Addington, J, Badrising, U, Barroso, F, Bateman, K, Bella, I, Benedetti, L, van den Berg, B, Bhavaraju-Sanka, R, Briani, C, Buermann, J, Busby, M, Butterworth, S, Casasnovas, C, Chen, S, Claeys, K, Conti, E, Cosgrove, J, Dalakas, M, van Damme, P, Dardiotis, E, Davidson, A, Doets, A, van Doorn, P, Echaniz-Laguna, A, Eftimov, F, Faber, K, Fazio, R, Feasby, T, Fehmi, J, Fokke, C, Fujioka, T, Fulgenzi, E, Garssen, M, Gijsbers, C, Gilchrist, J, Gilhuis, J, Goldstein, J, Gorson, K, Goyal, N, Granit, V, Gutmann, L, Hartung, H, Holt, J, Hsieh, S, Htut, M, Hughes, R, Jerico-Pascual, I, Kaida, K, Karafiath, S, Khoshnoodi, M, Kiers, L, Kleiweg, R, Kokubun, N, Kolb, N, van Koningsveld, R, van der Kooi, A, Kramers, H, Kuitwaard, K, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Lehmann, H, Cejas, L, Leonhard, S, Luijten, L, Lunn, M, Manji, H, Marfia, G, Infante, C, Martin-Aguilar, L, Martinez-Hernandez, E, Mataluni, G, Mattiazzi, M, Mcdermott, C, Meekins, G, Mohammad, Q, Monges, S, de la Tassa, G, Nascimbene, C, Nobile-Orazio, E, Nowak, R, Osei-Bonsu, M, Pelouto, F, Pulley, M, Gutierrez, L, Reddel, S, van der Ree, T, Rinaldi, S, Ripellino, P, Roberts, R, Rojas-Marcos, I, Roodbol, J, Rudnicki, S, Sachs, G, Samijn, J, Santoro, L, Schenone, A, Tous, M, Sheikh, K, Silvestri, N, Sundrup, S, Sommer, C, Stein, B, Stino, A, Thomma, R, Twydell, P, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Walgaard, C, Wang, Y, Willison, H, Wirtz, P, van Woerkom, M, Zivkovic, S, Arends S., Drenthen J., de Koning L., van den Bergh P., Hadden R. D. M., Kuwabara S., Reisin R. C., Shahrizaila N., Ajroud-Driss S., Antonini G., Attarian S., Balducci C., Bertorini T., Brannagan T. H., Cavaletti G., Chao C. -C., Chavada G., Dillmann K. -U., Dimachkie M. M., Galassi G., Gutierrez-Gutierrez G., Harbo T., Islam B., Islam Z., Katzberg H., Kusunoki S., Manganelli F., Miller J. A. L., Pardo J., Pereon Y., Rajabally Y. A., Sindrup S., Stettner M., Uncini A., Verhamme C., Vytopil M., Waheed W., Jacobs B. C., Cornblath D. R., Addington J. M., Badrising U. A., Barroso F. A., Bateman K., Bella I., Benedetti L., van den Berg B., Bhavaraju-Sanka R., Briani C., Buermann J., Busby M., Butterworth S., Casasnovas C., Chen S., Claeys K., Conti E., Cosgrove J. S., Dalakas M., van Damme P., Dardiotis E., Davidson A., Doets A., van Doorn P., Echaniz-Laguna A., Eftimov F., Faber K. G., Fazio R., Feasby T. E., Fehmi J., Fokke C., Fujioka T., Fulgenzi E., Garssen M. P. J., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Goldstein J. M., Gorson K. C., Goyal N., Granit V., Gutmann L., Hartung H. -P., Holt J. K. L., Hsieh S. -T., Htut M., Hughes R. A. C., Jerico-Pascual I., Kaida K., Karafiath S., Khoshnoodi M. A., Kiers L., Kleiweg R. P., Kokubun N., Kolb N. A., van Koningsveld R., van der Kooi A. J., Kramers H., Kuitwaard K., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V. H., Lehmann H., Cejas L. L., Leonhard S. E., Luijten L., Lunn M. P. T., Manji H., Marfia G. A., Infante C. M., Martin-Aguilar L., Martinez-Hernandez E., Mataluni G., Mattiazzi M., McDermott C., Meekins G., Mohammad Q. D., Monges S., de la Tassa G. M., Nascimbene C., Nobile-Orazio E., Nowak R. J., Osei-Bonsu M., Pelouto F., Pulley M. T., Gutierrez L. Q., Reddel S. W., van der Ree T., Rinaldi S., Ripellino P., Roberts R. C., Rojas-Marcos I., Roodbol J., Rudnicki S. A., Sachs G. M., Samijn J. P. A., Santoro L., Schenone A., Tous M. J. S., Sheikh K. A., Silvestri N. J., Sundrup S. H., Sommer C., Stein B., Stino A. M., Thomma R. C. M., Twydell P., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Walgaard C., Wang Y., Willison H. J., Wirtz P. W., van Woerkom M., and Zivkovic S. A.
Abstract: Background and purpose: Various electrodiagnostic criteria have been developed in Guillain–Barré syndrome (GBS). Their performance in a broad representation of GBS patients has not been evaluated. Motor conduction data from the International GBS Outcome Study (IGOS) cohort were used to compare two widely used criterion sets and relate these to diagnostic amyotrophic lateral sclerosis criteria. Methods: From the first 1500 patients in IGOS, nerve conduction studies from 1137 (75.8%) were available for the current study. These patients were classified according to nerve conduction studies criteria proposed by Hadden and Rajabally. Results: Of the 1137 studies, 68.3% (N = 777) were classified identically according to criteria by Hadden and Rajabally: 111 (9.8%) axonal, 366 (32.2%) demyelinating, 195 (17.2%) equivocal, 35 (3.1%) inexcitable and 70 (6.2%) normal. Thus, 360 studies (31.7%) were classified differently. The areas of differences were as follows: 155 studies (13.6%) classified as demyelinating by Hadden and axonal by Rajabally; 122 studies (10.7%) classified as demyelinating by Hadden and equivocal by Rajabally; and 75 studies (6.6%) classified as equivocal by Hadden and axonal by Rajabally. Due to more strictly defined cutoffs fewer patients fulfilled demyelinating criteria by Rajabally than by Hadden, making more patients eligible for axonal or equivocal classification by Rajabally. In 234 (68.6%) axonal studies by Rajabally the revised El Escorial (amyotrophic lateral sclerosis) criteria were fulfilled; in axonal cases by Hadden this was 1.8%. Conclusions and discussion: This study shows that electrodiagnosis in GBS is dependent on the criterion set utilized, both of which are based on expert opinion. Reappraisal of electrodiagnostic subtyping in GBS is warranted.
Published: 2024

2. Preconditioned quantum linear system algorithm

Author: Clader, B. D., Jacobs, B. C., and Sprouse, C. R.
Subjects: Quantum Physics
Abstract: We describe a quantum algorithm that generalizes the quantum linear system algorithm [Harrow et al., Phys. Rev. Lett. 103, 150502 (2009)] to arbitrary problem specifications. We develop a state preparation routine that can initialize generic states, show how simple ancilla measurements can be used to calculate many quantities of interest, and integrate a quantum-compatible preconditioner that greatly expands the number of problems that can achieve exponential speedup over classical linear systems solvers. To demonstrate the algorithm's applicability, we show how it can be used to compute the electromagnetic scattering cross section of an arbitrary target exponentially faster than the best classical algorithm., Comment: 5 pages; Substantial revisions, including addition of preconditioner
Published: 2013
Full Text: View/download PDF

3. All-Optical Switching Demonstration using Two-Photon Absorption and the Classical Zeno Effect

Author: Hendrickson, S. M., Weiler, C. N., Camacho, R. M., Rakich, P. T., Young, A. I., Shaw, M. J., Pittman, T. B., Franson, J. D., and Jacobs, B. C.
Subjects: Quantum Physics, Physics - Optics
Abstract: Low-contrast all-optical Zeno switching has been demonstrated in a silicon nitride microdisk resonator coupled to a hot atomic vapor. The device is based on the suppression of the field build-up within a microcavity due to non-degenerate two-photon absorption. This experiment used one beam in a resonator and one in free-space due to limitations related to device physics. These results suggest that a similar scheme with both beams resonant in the cavity would correspond to input power levels near 20 nW., Comment: 4 pages, 5 figures
Published: 2012
Full Text: View/download PDF

4. All-Optical Switching Using the Quantum Zeno Effect and Two-Photon Absorption

Author: Jacobs, B. C. and Franson, J. D.
Subjects: Quantum Physics
Abstract: We have previously shown that the quantum Zeno effect can be used to implement quantum logic gates for quantum computing applications, where the Zeno effect was produced using a strong two-photon absorbing medium. Here we show that the Zeno effect can also be used to implement classical logic gates whose inputs and outputs are high-intensity fields (coherent states). The operation of the devices can be understood using a quasi-static analysis, and their switching times are calculated using a dynamic approach. The two-photon absorption coefficient of rubidium vapor is shown to allow operation of these devices at relatively low power levels., Comment: 21 pages, 11 figures. Submitted to Phys. Rev. A
Published: 2009
Full Text: View/download PDF

5. Investigation of a single-photon source based on quantum interference

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: We report on an experimental investigation of a single-photon source based on a quantum interference effect first demonstrated by Koashi, Matsuoka, and Hirano [Phys. Rev. A 53, 3621 (1996)]. For certain types of measurement-based quantum information processing applications this technique may be useful as a high rate, but random, source of single photons., Comment: Submitted to the New J. Phys. Focus Issue on "Measurement-based quantum information processing"
Published: 2007
Full Text: View/download PDF

6. Zeno logic gates using micro-cavities

Author: Franson, J. D., Jacobs, B. C., and Pittman, T. B.
Subjects: Quantum Physics
Abstract: The linear optics approach to quantum computing has several potential advantages but the logic operations are probabilistic. Here we review the use of the quantum Zeno effect to suppress the intrinsic failure events in these kinds of devices, which would produce deterministic logic operations without the need for ancilla photons or high-efficiency detectors. The potential advantages of implementing Zeno gates using micro-cavities and electromagnetically-induced transparency are discussed., Comment: 22 pages, 8 figures
Published: 2006
Full Text: View/download PDF

7. Single Photon Source Using Laser Pulses and Two-Photon Absorption

Author: Jacobs, B. C., Pittman, T. B., and Franson, J. D.
Subjects: Quantum Physics
Abstract: We have previously shown that two-photon absorption (TPA) and the quantum Zeno effect can be used to make deterministic quantum logic devices from an otherwise linear optical system. Here we show that this type of quantum Zeno gate can be used with additional two-photon absorbing media and weak laser pulses to make a heralded single photon source. A source of this kind is expected to have a number of practical advantages that make it well suited for large scale quantum information processing applications.
Published: 2006
Full Text: View/download PDF

8. Demonstration of Quantum Error Correction using Linear Optics

Author: Pittman, T. B., Jacobs, B. C, and Franson, J. D.
Subjects: Quantum Physics
Abstract: We describe a laboratory demonstration of a quantum error correction procedure that can correct intrinsic measurement errors in linear-optics quantum gates. The procedure involves a two-qubit encoding and fast feed-forward-controlled single-qubit operations. In our demonstration the qubits were represented by the polarization states of two single-photons from a parametric down-conversion source, and the real-time feed-forward control was implemented using an electro-optic device triggered by the output of single-photon detectors., Comment: 5 pages, 3 figures; v2 has updated references
Published: 2005
Full Text: View/download PDF

9. Quantum Computing Using Single Photons and the Zeno Effect

Author: Franson, J. D., Jacobs, B. C., and Pittman, T. B.
Subjects: Quantum Physics
Abstract: We show that the quantum Zeno effect can be used to suppress the failure events that would otherwise occur in a linear optics approach to quantum computing. From a practical viewpoint, that would allow the implementation of deterministic logic gates without the need for ancilla photons or high-efficiency detectors. We also show that the photons can behave as if they were fermions instead of bosons in the presence of a strong Zeno effect, which leads to a new paradigm for quantum computation., Comment: 34 pages, 10 figures, longer version of quant-ph/0401133
Published: 2004
Full Text: View/download PDF

10. Heralding Single Photons from Pulsed Parametric Down-Conversion

Author: Pittman, T. B., Jacobs, B. C, and Franson, J. D.
Subjects: Quantum Physics
Abstract: We describe an experiment in which photon pairs from a pulsed parametric down-conversion source were coupled into single-mode fibers. Detecting one of the photons heralded the presence of the other photon in its fiber with a probability of 83%. The heralded photons were then used in a simple multi-photon interference experiment to illustrate their potential for quantum information applications., Comment: 4 pages, 7 figures. Version 2 has minor revisions
Published: 2004
Full Text: View/download PDF

11. Quantum Computing using Linear Optics

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: Quantum computers are expected to be able to solve mathematical problems that cannot be solved using conventional computers. Many of these problems are of practical importance, especially in the areas of cryptography and secure communications. APL is developing an optical approach to quantum computing in which the bits, or "qubits", are represented by single photons. Our approach allows the use of ordinary (linear) optical elements that are available for the most part as off-the-shelf components. Recent experimental demonstrations of a variety of logic gates for single photons, a prototype memory device, and other devices will be described., Comment: JHU-APL internal review article
Published: 2004

12. Experimental Demonstration of a Quantum Circuit using Linear Optics Gates

Author: Pittman, T. B., Jacobs, B. C, and Franson, J. D.
Subjects: Quantum Physics
Abstract: One of the main advantages of an optical approach to quantum computing is the fact that optical fibers can be used to connect the logic and memory devices to form useful circuits, in analogy with the wires of a conventional computer. Here we describe an experimental demonstration of a simple quantum circuit of that kind in which two probabilistic exclusive-OR (XOR) logic gates were combined to calculate the parity of three input qubits., Comment: v2 is final PRA version
Published: 2004
Full Text: View/download PDF

13. Quantum Logic Using Linear Optics

Author: Franson, J. D., Jacobs, B. C., and Pittman, T. B.
Subjects: Quantum Physics
Abstract: In order for quantum communications systems to become widely used, it will probably be necessary to develop quantum repeaters that can extend the range of quantum key distribution systems and correct for errors in the transmission of quantum information. Quantum logic gates based on linear optical techniques appear to be a promising approach for the development of quantum repeaters, and they may have applications in quantum computing as well. Here we describe the basic principles of logic gates based on linear optics, along with the results from several experimental demonstrations of devices of this kind. A prototype source of single photons and a quantum memory device for photons are also discussed. These devices can be combined with a four-qubit encoding to implement a quantum repeater., Comment: 31 pages, 15 figures
Published: 2004

14. Probabilistic Quantum Encoder for Single-Photon Qubits

Author: Pittman, T. B., Jacobs, B. C, and Franson, J. D.
Subjects: Quantum Physics
Abstract: We describe an experiment in which a physical qubit represented by the polarization state of a single-photon was probabilistically encoded in the logical state of two photons. The experiment relied on linear optics, post-selection, and three-photon interference effects produced by a parametric down-conversion photon pair and a weak coherent state. An interesting consequence of the encoding operation was the ability to observe entangled three-photon Greenberger-Horne-Zeilinger states., Comment: 4 pages, 4 figures; submitted to Phys. Rev. A
Published: 2003
Full Text: View/download PDF

15. Photon number resolution using a time-multiplexed single-photon detector

Author: Fitch, M. J., Jacobs, B. C., Pittman, T. B., and Franson, J. D.
Subjects: Quantum Physics
Abstract: Photon number resolving detectors are needed for a variety of applications including linear-optics quantum computing. Here we describe the use of time-multiplexing techniques that allows ordinary single photon detectors, such as silicon avalanche photodiodes, to be used as photon number-resolving detectors. The ability of such a detector to correctly measure the number of photons for an incident number state is analyzed. The predicted results for an incident coherent state are found to be in good agreement with the results of a proof-of-principle experimental demonstration., Comment: REVTeX4, 6 pages, 8 eps figures, v2: minor changes, v3: changes in response to referee report, appendix added, 1 reference added
Published: 2003
Full Text: View/download PDF

16. Generation of entangled ancilla states for use in linear optics quantum computing

Author: Franson, J. D., Donegan, M. M., and Jacobs, B. C.
Subjects: Quantum Physics
Abstract: We describe several different methods for generating the entangled ancilla states that are required for linear optics quantum computing. We show that post-selection can be used in combination with linear optical elements to generate the entangled ancilla, but with an exponentially-small efficiency. Alternatively, the ancilla can be efficiently generated using solid-state devices consisting of quantum wells coupled with tunnel junctions. Finally, we consider the possibility of using encoded ancilla in order to reduce the effects of decoherence and measurement errors., Comment: 23 pages, 10 figures
Published: 2003
Full Text: View/download PDF

17. Heralded Two-Photon Entanglement from Probabilistic Quantum Logic Operations on Multiple Parametric Down-Conversion Sources

Author: Pittman, T. B., Donegan, M. M., Fitch, M. J., Jacobs, B. C., Franson, J. D., Kok, P., Lee, H., and Dowling, J. P.
Subjects: Quantum Physics
Abstract: An ideal controlled-NOT gate followed by projective measurements can be used to identify specific Bell states of its two input qubits. When the input qubits are each members of independent Bell states, these projective measurements can be used to swap the post-selected entanglement onto the remaining two qubits. Here we apply this strategy to produce heralded two-photon polarization entanglement using Bell states that originate from independent parametric down-conversion sources, and a particular probabilistic controlled-NOT gate that is constructed from linear optical elements. The resulting implementation is closely related to an earlier proposal by Sliwa and Banaszek [quant-ph/0207117], and can be intuitively understood in terms of familiar quantum information protocols. The possibility of producing a ``pseudo-demand'' source of two-photon entanglement by storing and releasing these heralded pairs from independent cyclical quantum memory devices is also discussed., Comment: 5 pages, 4 figures; submitted to IEEE Journal of Selected Topics in Quantum Electronics, special issue on "Quantum Internet Technologies"
Published: 2003
Full Text: View/download PDF

18. Experimental Controlled-NOT Logic Gate for Single Photons in the Coincidence Basis

Author: Pittman, T. B., Fitch, M. J., Jacobs, B. C, and Franson, J. D.
Subjects: Quantum Physics
Abstract: We report a proof-of-principle demonstration of a probabilistic controlled-NOT gate for single photons. Single-photon control and target qubits were mixed with a single ancilla photon in a device constructed using only linear optical elements. The successful operation of the controlled-NOT gate relied on post-selected three-photon interference effects which required the detection of the photons in the output modes., Comment: 4 pages, 4 figures; minor changes
Published: 2003
Full Text: View/download PDF

19. Single Photons on Pseudo-Demand from Stored Parametric Down-Conversion

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: We describe the results of a parametric down-conversion experiment in which the detection of one photon of a pair causes the other photon to be switched into a storage loop. The stored photon can then be switched out of the loop at a later time chosen by the user, providing a single photon for potential use in a variety of quantum information processing applications. Although the stored single photon is only available at periodic time intervals, those times can be chosen to match the cycle time of a quantum computer by using pulsed down-conversion. The potential use of the storage loop as a photonic quantum memory device is also discussed., Comment: 8 pages, 7 Figs., RevTex
Published: 2002
Full Text: View/download PDF

20. Demonstration of Feed-Forward Control for Linear Optics Quantum Computation

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: One of the main requirements in linear optics quantum computing is the ability to perform single-qubit operations that are controlled by classical information fed forward from the output of single photon detectors. These operations correspond to pre-determined combinations of phase corrections and bit-flips that are applied to the post-selected output modes of non-deterministic quantum logic devices. Corrections of this kind are required in order to obtain the correct logical output for certain detection events, and their use can increase the overall success probability of the devices. In this paper, we report on the experimental demonstration of the use of this type of feed-forward system to increase the probability of success of a simple non-deterministic quantum logic operation from approximately 1/4 to 1/2. This logic operation involves the use of one target qubit and one ancilla qubit which, in this experiment, are derived from a parametric down-conversion photon pair. Classical information describing the detection of the ancilla photon is fed-forward in real-time and used to alter the quantum state of the output photon. A fiber optic delay line is used to store the output photon until a polarization-dependent phase shift can be applied using a high speed Pockels cell.
Published: 2002
Full Text: View/download PDF

21. Quantum relays and noise suppression using linear optics

Author: Jacobs, B. C., Pittman, T. B., and Franson, J. D.
Subjects: Quantum Physics
Abstract: Probabilistic quantum non-demolition (QND) measurements can be performed using linear optics and post-selection. Here we show how QND devices of this kind can be used in a straightforward way to implement a quantum relay, which is capable of extending the range of a quantum cryptography system by suppressing the effects of detector noise. Unlike a quantum repeater, a quantum relay system does not require entanglement purification or the ability to store photons., Comment: minor changes; references added
Published: 2002
Full Text: View/download PDF

22. High-fidelity quantum logic operations using linear optical elements

Author: Franson, J. D., Donegan, M. M., Fitch, M. J., Jacobs, B. C., and Pittman, T. B.
Subjects: Quantum Physics
Abstract: Knill, Laflamme, and Milburn [Nature 409, 46 (2001)] have shown that quantum logic operations can be performed using linear optical elements and additional ancilla photons. Their approach is probabilistic in the sense that the logic devices fail to produce an output with a failure rate that scales as 1/n, where n is the number of ancilla. Here we present an alternative approach in which the logic devices always produce an output with an intrinsic error rate that scales as 1/n^2,which may have several advantages in quantum computing applications., Comment: 13 pages, 3 figures
Published: 2002
Full Text: View/download PDF

23. Demonstration of Non-Deterministic Quantum Logic Operations using Linear Optical Elements

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: Knill, Laflamme, and Milburn recently showed that non-deterministic quantum logic operations could be performed using linear optical elements, additional photons (ancilla), and post-selection based on the output of single-photon detectors [Nature 409, 46 (2001)]. Here we report the experimental demonstration of two logic devices of this kind, a destructive controlled-NOT (CNOT) gate and a quantum parity check. These two devices can be combined with a pair of entangled photons to implement a conventional (non-destructive) CNOT that succeeds with a probability of 1/4., Comment: 4 pages, 5 figures; Minor changes
Published: 2001
Full Text: View/download PDF

24. Probabilistic Quantum Logic Operations Using Polarizing Beam Splitters

Author: Pittman, T. B., Jacobs, B. C., and Franson, J. D.
Subjects: Quantum Physics
Abstract: It has previously been shown that probabilistic quantum logic operations can be performed using linear optical elements, additional photons (ancilla), and post-selection based on the output of single-photon detectors. Here we describe the operation of several quantum logic operations of an elementary nature, including a quantum parity check and a quantum encoder, and we show how they can be combined to implement a controlled-NOT (CNOT) gate. All of these gates can be constructed using polarizing beam splitters that completely transmit one state of polarization and totally reflect the orthogonal state of polarization, which allows a simple explanation of each operation. We also describe a polarizing beam splitter implementation of a CNOT gate that is closely analogous to the quantum teleportation technique previously suggested by Gottesman and Chuang [Nature 402, p.390 (1999)]. Finally, our approach has the interesting feature that it makes practical use of a quantum-eraser technique., Comment: 9 pages, RevTex; Submitted to Phys. Rev. A; additional references inlcuded
Published: 2001
Full Text: View/download PDF

25. CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome

Author: Al-Hakem, H, Doets, A, Stino, A, Zivkovic, S, Andersen, H, Willison, H, Cornblath, D, Gorson, K, Islam, Z, Mohammad, Q, Sindrup, S, Kusunoki, S, Davidson, A, Casasnovas, C, Bateman, K, Miller, J, Van Den Berg, B, Verboon, C, Roodbol, J, Leonhard, S, Arends, S, Luijten, L, Benedetti, L, Kuwabara, S, Van Den Bergh, P, Monges, S, Marfia, G, Shahrizaila, N, Galassi, G, Pereon, Y, Burmann, J, Kuitwaard, K, Kleyweg, R, Marchesoni, C, Tous, M, Querol, L, Martin-Aguilar, L, Wang, Y, Nobile-Orazio, E, Rinaldi, S, Schenone, A, Pardo, J, Vermeij, F, Waheed, W, Lehmann, H, Granit, V, Stein, B, Cavaletti, G, Gutierrez-Gutierrez, G, Barroso, F, Visser, L, Katzberg, H, Dardiotis, E, Attarian, S, Van Der Kooi, A, Eftimov, F, Wirtz, P, Samijn, J, Jacobus Gilhuis, H, Hadden, R, Holt, J, Sheikh, K, Kolb, N, Karafiath, S, Vytopil, M, Antonini, G, Feasby, T, Faber, C, Kramers, H, Busby, M, Roberts, R, Silvestri, N, Fazio, R, Van Dijk, G, Garssen, M, Verschuuren, J, Harbo, T, Jacobs, B, Al-Hakem H., Doets A. Y., Stino A. M., Zivkovic S. A., Andersen H., Willison H. J., Cornblath D. R., Gorson K. C., Islam Z., Mohammad Q. D., Sindrup So. H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J. A. L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S. E., Arends S., Luijten L. W. G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G. A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R. P., Marchesoni C., Tous M. J. S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F. H., Waheed W., Lehmann H. C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F. A., Visser L. H., Katzberg H. D., Dardiotis E., Attarian S., Van Der Kooi A. J., Eftimov F., Wirtz P. W., Samijn J. P. A., Jacobus Gilhuis H., Hadden R. D. M., Holt J. K. L., Sheikh K. A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T. E., Faber C., Kramers H., Busby M., Roberts R. C., Silvestri N. J., Fazio R., Van Dijk G. W., Garssen M. P. J., Verschuuren J., Harbo T., Jacobs B. C., Al-Hakem, H, Doets, A, Stino, A, Zivkovic, S, Andersen, H, Willison, H, Cornblath, D, Gorson, K, Islam, Z, Mohammad, Q, Sindrup, S, Kusunoki, S, Davidson, A, Casasnovas, C, Bateman, K, Miller, J, Van Den Berg, B, Verboon, C, Roodbol, J, Leonhard, S, Arends, S, Luijten, L, Benedetti, L, Kuwabara, S, Van Den Bergh, P, Monges, S, Marfia, G, Shahrizaila, N, Galassi, G, Pereon, Y, Burmann, J, Kuitwaard, K, Kleyweg, R, Marchesoni, C, Tous, M, Querol, L, Martin-Aguilar, L, Wang, Y, Nobile-Orazio, E, Rinaldi, S, Schenone, A, Pardo, J, Vermeij, F, Waheed, W, Lehmann, H, Granit, V, Stein, B, Cavaletti, G, Gutierrez-Gutierrez, G, Barroso, F, Visser, L, Katzberg, H, Dardiotis, E, Attarian, S, Van Der Kooi, A, Eftimov, F, Wirtz, P, Samijn, J, Jacobus Gilhuis, H, Hadden, R, Holt, J, Sheikh, K, Kolb, N, Karafiath, S, Vytopil, M, Antonini, G, Feasby, T, Faber, C, Kramers, H, Busby, M, Roberts, R, Silvestri, N, Fazio, R, Van Dijk, G, Garssen, M, Verschuuren, J, Harbo, T, Jacobs, B, Al-Hakem H., Doets A. Y., Stino A. M., Zivkovic S. A., Andersen H., Willison H. J., Cornblath D. R., Gorson K. C., Islam Z., Mohammad Q. D., Sindrup So. H., Kusunoki S., Davidson A., Casasnovas C., Bateman K., Miller J. A. L., Van Den Berg B., Verboon C., Roodbol J., Leonhard S. E., Arends S., Luijten L. W. G., Benedetti L., Kuwabara S., Van Den Bergh P., Monges S., Marfia G. A., Shahrizaila N., Galassi G., Pereon Y., Burmann J., Kuitwaard K., Kleyweg R. P., Marchesoni C., Tous M. J. S., Querol L., Martin-Aguilar L., Wang Y., Nobile-Orazio E., Rinaldi S., Schenone A., Pardo J., Vermeij F. H., Waheed W., Lehmann H. C., Granit V., Stein B., Cavaletti G., Gutierrez-Gutierrez G., Barroso F. A., Visser L. H., Katzberg H. D., Dardiotis E., Attarian S., Van Der Kooi A. J., Eftimov F., Wirtz P. W., Samijn J. P. A., Jacobus Gilhuis H., Hadden R. D. M., Holt J. K. L., Sheikh K. A., Kolb N., Karafiath S., Vytopil M., Antonini G., Feasby T. E., Faber C., Kramers H., Busby M., Roberts R. C., Silvestri N. J., Fazio R., Van Dijk G. W., Garssen M. P. J., Verschuuren J., Harbo T., and Jacobs B. C.
Abstract: Background and ObjectivesTo investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.MethodsAlbuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/L). We excluded 124 (8%) patients because of other diagnoses, protocol violation, or insufficient data. The CSF was examined in 1,231 patients (89%).ResultsIn 846 (70%) patients, CSF examination showed ACD, which increased with time from weakness onset: ≤4 days 57%, >4 days 84%. High CSF protein levels were associated with a demyelinating subtype, proximal or global muscle weakness, and a reduced likelihood of being able to run at week 2 (odds ratio [OR] 0.42, 95% CI 0.25-0.70; p = 0.001) and week 4 (OR 0.44, 95% CI 0.27-0.72; p = 0.001). Patients with the Miller Fisher syndrome, distal predominant weakness, and normal or equivocal nerve conduction studies were more likely to have lower CSF protein levels. CSF cell count was <5 cells/L in 1,005 patients (83%), 5-49 cells/L in 200 patients (16%), and ≥50 cells/L in 13 patients (1%).DiscussionACD is a common finding in GBS, but normal protein levels do not exclude this diagnosis. High CSF protein level is associated with an early severe disease course and a demyelinating subtype. Elevated CSF cell count, rarely ≥50 cells/L, is compatible with GBS after a thorough exclusion of alternative diagnoses.Classification of EvidenceThis study provides Class IV evidence that CSF ACD (defined by the Brighton Collaboration) is common in patients with GBS.
Published: 2023

26. Predicting respiratory failure and outcome in pediatric Guillain-Barré syndrome

Author: Roodbol, Joyce, Korinthenberg, Rudolf, Venema, Esmee, de Wit, M. C.Y., Lingsma, Hester F., Catsman-Berrevoets, Coriene E., Jacobs, B. C., Korinthenberg, R., Catsman-Berrevoets, C. E., Engelen, M., Erasmus, C. E., Geleijns, C. P.W., Kotsopoulos, I. A.W., Nicolai, J., Niermeijer, J. M.F., Niks, E. H., Samijn, J., Roodbol, Joyce, Korinthenberg, Rudolf, Venema, Esmee, de Wit, M. C.Y., Lingsma, Hester F., Catsman-Berrevoets, Coriene E., Jacobs, B. C., Korinthenberg, R., Catsman-Berrevoets, C. E., Engelen, M., Erasmus, C. E., Geleijns, C. P.W., Kotsopoulos, I. A.W., Nicolai, J., Niermeijer, J. M.F., Niks, E. H., and Samijn, J.
Abstract: Background: Guillain-Barré syndrome (GBS) has a highly variable clinical course and outcome as indicated by the risk of developing respiratory failure and residual inability to walk. Prognostic models as Erasmus GBS Respiratory Insufficiency Score (EGRIS) developed in adult patients are inaccurate in children. Our aim was to determine the prognostic factors of respiratory failure and inability to walk in children with GBS and to develop a new clinical prognostic model for individual patients (EGRIS-Kids). Methods: A multicenter retrospective cohort study was performed using the data of children (younger than 18 years) fulfilling the diagnostic criteria for GBS from the NINDS. This study was performed in two independent cohorts from centers in Germany, Switzerland, Austria (N = 265, collected 1989–2002) and The Netherlands (N = 156, collected 1987–2016). The predicted main outcomes were occurrence of respiratory failure during the disease course and inability to walk independent at one year after diagnosis. Results: In the combined cohort of 421 children, 79 (19%) required mechanical ventilation and one patient died. The EGRIS-kids was developed including: age, cranial nerve involvement and GBS disability score at admission, resulting in a 9 point score predicting risks of respiratory failure ranging from 4 to 50% (AUC = 0.71). A lower GBS disability score at nadir was the strongest predictor of recovery to independent walking (at one month: OR 0.43 95%CI 0.25–0.74). Conclusions: EGRIS-Kids and GBS disability score at admission accurately predict the risk of respiratory failure and inability to walk respectively in children with GBS, as tools to personalize the monitoring and treatment.
Published: 2023

27. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values

Author: Arends, S, Drenthen, J, van den Bergh, P, Franssen, H, Hadden, R, Islam, B, Kuwabara, S, Reisin, R, Shahrizaila, N, Amino, H, Antonini, G, Attarian, S, Balducci, C, Barroso, F, Bertorini, T, Binda, D, Brannagan, T, Buermann, J, Casasnovas, C, Cavaletti, G, Chao, C, Dimachkie, M, Fulgenzi, E, Galassi, G, Gutierrez Gutierrez, G, Harbo, T, Hartung, H, Hsieh, S, Kiers, L, Lehmann, H, Manganelli, F, Marfia, G, Mataluni, G, Pardo, J, Pereon, Y, Rajabally, Y, Santoro, L, Sekiguchi, Y, Stein, B, Stettner, M, Uncini, A, Verboon, C, Verhamme, C, Vytopil, M, Waheed, W, Wang, M, Zivkovic, S, Jacobs, B, Cornblath, D, Arends S., Drenthen J., van den Bergh P., Franssen H., Hadden R. D. M., Islam B., Kuwabara S., Reisin R. C., Shahrizaila N., Amino H., Antonini G., Attarian S., Balducci C., Barroso F., Bertorini T., Binda D., Brannagan T. H., Buermann J., Casasnovas C., Cavaletti G., Chao C. -C., Dimachkie M. M., Fulgenzi E. A., Galassi G., Gutierrez Gutierrez G., Harbo T., Hartung H. -P., Hsieh S. -T., Kiers L., Lehmann H. C., Manganelli F., Marfia G. A., Mataluni G., Pardo J., Pereon Y., Rajabally Y. A., Santoro L., Sekiguchi Y., Stein B., Stettner M., Uncini A., Verboon C., Verhamme C., Vytopil M., Waheed W., Wang M., Zivkovic S., Jacobs B. C., Cornblath D. R., Arends, S, Drenthen, J, van den Bergh, P, Franssen, H, Hadden, R, Islam, B, Kuwabara, S, Reisin, R, Shahrizaila, N, Amino, H, Antonini, G, Attarian, S, Balducci, C, Barroso, F, Bertorini, T, Binda, D, Brannagan, T, Buermann, J, Casasnovas, C, Cavaletti, G, Chao, C, Dimachkie, M, Fulgenzi, E, Galassi, G, Gutierrez Gutierrez, G, Harbo, T, Hartung, H, Hsieh, S, Kiers, L, Lehmann, H, Manganelli, F, Marfia, G, Mataluni, G, Pardo, J, Pereon, Y, Rajabally, Y, Santoro, L, Sekiguchi, Y, Stein, B, Stettner, M, Uncini, A, Verboon, C, Verhamme, C, Vytopil, M, Waheed, W, Wang, M, Zivkovic, S, Jacobs, B, Cornblath, D, Arends S., Drenthen J., van den Bergh P., Franssen H., Hadden R. D. M., Islam B., Kuwabara S., Reisin R. C., Shahrizaila N., Amino H., Antonini G., Attarian S., Balducci C., Barroso F., Bertorini T., Binda D., Brannagan T. H., Buermann J., Casasnovas C., Cavaletti G., Chao C. -C., Dimachkie M. M., Fulgenzi E. A., Galassi G., Gutierrez Gutierrez G., Harbo T., Hartung H. -P., Hsieh S. -T., Kiers L., Lehmann H. C., Manganelli F., Marfia G. A., Mataluni G., Pardo J., Pereon Y., Rajabally Y. A., Santoro L., Sekiguchi Y., Stein B., Stettner M., Uncini A., Verboon C., Verhamme C., Vytopil M., Waheed W., Wang M., Zivkovic S., Jacobs B. C., and Cornblath D. R.
Abstract: Objective: To describe the heterogeneity of electrodiagnostic (EDx) studies in Guillain-Barré syndrome (GBS) patients collected as part of the International GBS Outcome Study (IGOS). Methods: Prospectively collected clinical and EDx data were available in 957 IGOS patients from 115 centers. Only the first EDx study was included in the current analysis. Results: Median timing of the EDx study was 7 days (interquartile range 4–11) from symptom onset. Methodology varied between centers, countries and regions. Reference values from the responding 103 centers were derived locally in 49%, from publications in 37% and from a combination of these in the remaining 15%. Amplitude measurement in the EDx studies (baseline-to-peak or peak-to-peak) differed from the way this was done in the reference values, in 22% of motor and 39% of sensory conduction. There was marked variability in both motor and sensory reference values, although only a few outliers accounted for this. Conclusions: Our study showed extensive variation in the clinical practice of EDx in GBS patients among IGOS centers across the regions. Significance: Besides EDx variation in GBS patients participating in IGOS, this diversity is likely to be present in other neuromuscular disorders and centers. This underlines the need for standardization of EDx in future multinational GBS studies.
Published: 2022

28. Clinical outcome of CIDP one year after start of treatment:a prospective cohort study

Author: Bus, S. R.M., Broers, M. C., Lucke, I. M., Bunschoten, C., van Lieverloo, G. G.A., Adrichem, M. E., van Veen, R., Wieske, L., Lingsma, H. F., Goedee, H. S., van der Pol, W. L., van Schaik, I. N., Van Doorn, P. A., Jacobs, B. C., Eftimov, F., Bus, S. R.M., Broers, M. C., Lucke, I. M., Bunschoten, C., van Lieverloo, G. G.A., Adrichem, M. E., van Veen, R., Wieske, L., Lingsma, H. F., Goedee, H. S., van der Pol, W. L., van Schaik, I. N., Van Doorn, P. A., Jacobs, B. C., and Eftimov, F.
Abstract: Objective: To assess clinical outcome in treatment-naive patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods: We included adult treatment-naive patients participating in the prospective International CIDP Outcome Study (ICOS) that fulfilled the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria for CIDP. Patients were grouped based on initial treatment with (1) intravenous immunoglobulin (IVIg), (2) corticosteroid monotherapy or (3) IVIg and corticosteroids (combination treatment). Outcome measures included the inflammatory Rasch-built overall disability scale (I-RODS), grip strength, and Medical Research Council (MRC) sum score. Treatment response, treatment status, remissions (improved and untreated), treatment changes, and residual symptoms or deficits were assessed at 1 year. Results: Forty patients were included of whom 18 (45%) initially received IVIg, 6 (15%) corticosteroids, and 16 (40%) combination treatment. Improvement on ≥ 1 of the outcome measures was seen in 31 (78%) patients. At 1 year, 19 (48%) patients were still treated and fourteen (36%) patients were in remission. Improvement was seen most frequently in patients started on IVIg (94%) and remission in those started on combination treatment (44%). Differences between groups did not reach statistical significance. Residual symptoms or deficits ranged from 25% for neuropathic pain to 96% for any sensory deficit. Conclusions: Improvement was seen in most patients. One year after the start of treatment, more than half of the patients were untreated and around one-third in remission. Residual symptoms and deficits were common regardless of treatment.
Published: 2022

29. Immunoglobulin G Fc N-glycosylation in Guillain-Barré syndrome treated with intravenous immunoglobulin

Author: Fokkink, W.-J. R., Selman, M. H. C., Wuhrer, M., and Jacobs, B. C.
Published: 2014
Full Text: View/download PDF

30. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome. An international observational study

Author: Verboon, C., Harbo, T., Cornblath, D. R., Hughes, R. A. C., Van Doorn, P. A., Lunn, M. P., Gorson, K. C., Barroso, F., Kuwabara, S., Galassi, G., Lehmann, H. C., Kusunoki, S., Reisin, R. C., Binda, D., Cavaletti, G., Andersen, Jacobs B. C. H., PhD (Aarhus University Hospital, Aarhus, Denmark), Attarian, S., PhD (CHU Timone, Marseille, France), Badrising, U. A., PhD (Leiden University Medical Centre, Leiden, The, Netherlands), Bateman, K., PhD (Groote Schuur Hospital, Cape, Town, South-Africa), Benedetti, L., PhD (Ospedale Sant’ Andrea La Spezia, Spezia, La, Italy), van den Berg, B., MD (Franciscus Gasthuis, Rotterdam, Van den Bergh, P., Luc, PhD (University Clinic St., Leuven, Belgium), Bertorini, T. E., MD (The University of Tennessee Health Science Center (UTHSC), Memphis, USA), Bhavaraju-Sanka, R., MD (University Hospital/ University of Texas Health Science Center, San Antonio Texas, USA), Bianco (Milan University, M., Humanitas Clinicala and Research Institute Milan, Briani, C., MD (University of Padova, Padova, Italy), Bürmann, J., MD (Universitätsklinikum des Saarlandes, Homburg, Germany), Casasnovas, C., Ciberer, PhD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group., Barcelona, Spain), Chao, C. C., PhD (National Taiwan University Hospital, Taipei, Taiwan), Chavada, G., PhD (Glasgow University, Glasgow, UK), Claeys, K. G., University Hospitals Leuven, PhD (1., Leuven, Belgium, KU Leuven, 2., Cosgrove, J. S., MD (Leeds General Infirmary, Leeds, UK), Dalakas, M. C., Thomas Jefferson University, MD (1., Philadelphia, Usa, National and Kapodistrian University of Athens, 2., Athens, Greece), Davidson, A., MD (University of Glasgow, van Dijk, G. W., MD (Canisius Wilhelmina Hospital, Nijmegen, Dardiotis, E., MD (University of Thessaly, Hospital of Larissa, Larissa, Greece), Derejko, M., MD (Odense University Hospital, Odense, Denmark), Dimachkie, M. M., MD (University of Kansas Medical Center, Kansas, City, Dornonville de la Cour, C., MD (National Hospital Copenhagen, Copenhagen, Denmark), Echaniz-Laguna, A., MD (Bicêtre University Hospital, Paris, France), Eftimov, F., PhD (Amsterdam University Medical Centre, Amsterdam, Faber, C. G., PhD (Maastricht University Medical Centre, Maastricht, Fazio, R., MD (Scientific Institute San Raffaele, Milan, Italy), Fulgenzi, J. Fehmi (University of Oxford E. A., MD (Hospital Cesar Milstein Buenos Aires, Buenos, Aires, Argentina), García-Sobrino, T., MD (Hospital Clínico de Santiago, Santiago de Compostela (A Coruña), Spain), Gijsbers, C. J., MD (Vlietland Hospital, Schiedam, Granit, V., MD (Montefiore Medical, Center, New, York, Grisanti, S., MD (Ospedale Sant’ Andrea La Spezia, Gutiérrez-Gutiérrez, G., MD (Hospital Universitario Infanta Sofia, San, Sebastian, Holbech, J. V., PhD (Odense University Hospital, Holt, J. K. L., Phd, FRCP (The Walton Centre, Liverpool, UK), Homedes, C., Ciberer, MD (Bellvitge University Hospital - IDIBELL Neurometabolic Diseases Group., Islam, B., PhD (International Centre for Diarrhoeal Disease Research, Bangladesh, (icddr, Dhaka, b), Bangladesh), Islam, Z., Jahan, I., PhD candidate (International Centre for Diarrhoeal Disease Research, Jericó Pascual, I., PhD (Complejo Hospitalario de Navarra, Pamplona, Spain), Karafiath, S., MD (University of Utah School of Medicine, Salt Lake City, Kerkhoff, H., PhD (Albert Schweitzer Hospital, Dordrecht, Kimpinski, K., MD (University Hospital, Lhsc, London-Ontario, Canada), Kohler, A., MD (Instituto de Investigaciones Neurológicas Raúl Carrea, Fleni, Kolb, N., MD (University of Vermont, Burlington, Vt, Kuitwaard, K., Albert Schweitzer Hospital, PhD (1., Erasmus MC, 2., Kuwahara, M., PhD (Kindai University, Osaka, Japan), Ladha, S. S., MD (Barrow Neurology Clinics, Phoenix, Arizona, Lee Pan, E., MBChB (Groote Schuur Hospital, Marfia, G. A., MD (Neurological Clinic, Policlinico Tor Vergata, Rome, Italy), Magot, A., MD (Reference Centre for NMD, Nantes University Hospital, France), Márquez Infante, C., MD (Hospital Universitario Virgen del Rocio, Seville, Spain), Martín-Aguilar, L., MD (Hospital de la Santa Creu, i Sant Pau, Universitat Autònoma de Barcelona, Martinez Hernandez, E., MD (Institut d’Investigacions Biomèdiques August Pi, i Sunyer (IDIBAPS), Hospital, Clinic, Mataluni, G., PhD (Neurological Clinic, Meekins, G., MD (University of Minnesota, Miller, J. A. L., PhD (Royal Victoria Infirmary, Newcastle, UK), Monges, M. S., Garrahan, MD (Hospital de Pediatría J. P., Nobile Orazio, E., PhD (Milan University, Pardal, A., MD (Hospital Britanico, Pardo Fernandez (Hospital Clínico de Santiago, J., Péréon, Y., PhD (Reference Centre for NMD, Pulley, M., MD (University of Florida, Jacksonville, USA), Querol Gutierrez, L., PhD (Hospital de la Santa Creu, i Sant Pau, Reddel, S. W., PhD (Concord Repatriation General Hospital, Sydney, Australia), van der Ree, T., (Westfriesgasthuis, Md, Hoorn, Rinaldi, S., Mbchb, Samijn, PhD (University of Oxford J. P. A., MD (Maasstad Hospital, Samukawa, M., Santoro, L., PhD (University Federico II, Napels, Italy), Savransky, A., Garrahan, PhD (Hospital de Pediatría J. P., Schwindling, L., Sedano Tous, M. J., MD (Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Sekiguchi, Y., PhD (Chiba University, Chiba, Japan), Shahrizaila, N., MD (Neurology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Malaya), Silvestri, N. J., Sindrup, MD (Buffalo Jacobs School of Medicine S., Sommer, C. L., MD (Universitätsklinikum Würzburg, Würzburg, Germany), Spyropoulos (Royal Victoria Infirmary, A., Stein, B., Joseph’s Regional Medical Center, MD (St., Paterson, USA), Tan, C. Y., MRCP (Neurology Unit, Tankisi, H., Vermeij, F., Vytopil, M. V., Wirtz, PhD (Tufts University School of Medicine Lahey Hospital P. W., Phd, (HagaZiekenhuis, The, Hague, Waheed, W., MD (University of Vermont Medical Center, Burlington, Addington, USA). Other collaborators were:J. M., MD (University of Virginia, Charlottesville, USA), Ajroud-Driss, S., MD (Northwestern University Feinberg, Chicago, USA), Antonini, G., MD (Mental Health and Sensory Organs (NESMOS), Sapienza, University, Sant’Andrea, Hospital, Bella, I. R., MD (University of Mass Medical School, Worcester, USA), Brannagan, T. H., MD (Columbia University, New York City, Bunschoten, C., PhD candidate (Erasmus University Medical Centre, Busby, M., Bradford, UK), Butterworth, S., MD (Pinderfields Hospital, Wakefield, UK), Conti, M. E., MD (University Hospital Clinicas, Chen, S., Phd, (Rutgers, Robert Wood Johnson University Hospital, New, Brunswick, Doets, A., Feasby, T. E., MD (University of Calgary, Calgary, Canada), Fokke, C., MD (Gelre Hospital, Zutphen and Apeldoorn, Fujioka, T., MD (Toho University Medical Center, Tokyo, Japan), Garssen, M. P. J., PhD (Jeroen Bosch Hospital, Hertogenbosch, ’S, Gilchrist, J. M., MD (Soulthern Illinois University School of Medicine, Springfield, USA), Gilhuis, J., PhD (Reinier de Graaf Gasthuis, Delft, Goldstein, J. M., MD (Yale University School of Medicine, New, Haven, Goyal, N. A., MD (University of California, Irvine, USA), Hadden, R. D. M., PhD (King’s College Hospital, London, UK), Hsieh, S. T., Htut, M., George’s Hospital, MD (St., Illa, I., Jellema, K., PhD (Haaglanden Medisch Centrum, Kaida, K., PhD (National Defense Medical College, Saitama, Japan), Katzberg, H. D., MD (University of Toronto, Toronto, Canada), Kiers, L., MD (University of Melbourne, Royal Melbourne Hospital, Parkville, Australia), Kokubun, N., MD (Dokkyo Medical University, Tochigi, Japan), van Koningsveld, R., PhD (Elkerliek Hospital, Helmond and Deurne, van der Kooi, A. J., Kwan, J. Y., MD (University of Maryland School of Medicine, Baltimore, USA), Landschoff Lassen, L., MD (Glostrup Hospital, Glostrup, Denmark), Lawson, V., MD (Wexner Medical Center at The Ohio State University, Columbus, USA), Leonhard, S. E., Mandarakas, M., PhD (Erasmus University Medical Centre, Manji, H., FRCP (Ipswich Hospital, Ipswich, UK), Mattiazzi, M. G., MD (Hospital Militar Central, Mcdermott, C. J., MD (Royal Hallamshire Hospital, Nihr, Clinical, Sheffield, UK), Mohammad, Q. D., PhD (National Institute of Neurosciences and Hospital, Dhaka, Bangladesh), Morís de la Tassa, G., MD (Hospital UniversitarioCentral de Asturias, Asturias, Spain), Nascimbene, C., PhD (Luigi Sacco Hospital, Niks, E. H., Nowak, R. J., Osei-Bonsu, M., PhD (James Cook University Hospital, Middlesbrough, UK), Pascuzzi, R. M., MD (University of Indiana School of Medicine, Indianapolis, USA), Roberts, R. C., MD (Addenbrooke’s Hospital Cambridge, Cambridge, UK), Rojas-Marcos, I., MD (Hospital Univesitario Reina Sofia, Cordoba, Spain), Roodbol, J., Rudnicki, S. A., MD (University of Arkansas, Fayetteville, USA), Sachs, G. M., MD (University of Rhode Island, Providence, USA), Schenone, A., Department of Neurosciences, PhD (1., Rehabilitation, Ophthalmology, Genetics and Maternal and Infantile Sciences (DINOGMI), University of Genova, Genova, IRCCS Policlinico San Martino, Italy 2., Genova, Italy), Sheikh, K., PhD (The University of Texas Health Science Center at Houston, Houston, USA), Twydell, P., DO (Spectrum Health System, Grand, Rapids, Van Damme, P., PhD (University Hospital Leuven, Varrato, J. D., DO (Lehigh Valley Health Network, Allentown, USA), Visser, L. H., PhD (Elisabeth-TweeSteden Hospital, Tilburg and Waalwijk, Willison, H. J., PhD (University of Glasgow, van Woerkom (Erasmus MC, M., Zhou, L., PhD (Icahn School, Verboon, C, Harbo, T, Cornblath, D, Hughes, R, Van Doorn, P, Lunn, M, Gorson, K, Barroso, F, Kuwabara, S, Galassi, G, Lehmann, H, Kusunoki, S, Reisin, R, Binda, D, Cavaletti, G, Jacobs, B, consortium, IGOS, consortium, GOS, Neurosurgery, Neurology, and Immunology
Subjects: Adult, Male, medicine.medical_specialty, intravenous immunoglobulins, DIAGNOSIS, Guillain-Barre Syndrome, Settore MED/26, DISEASE, Disease course, Disability Evaluation, 03 medical and health sciences, 0302 clinical medicine, SDG 3 - Good Health and Well-being, hemic and lymphatic diseases, Internal medicine, Clinical endpoint, medicine, Humans, In patient, guillain-barré syndrome, 030212 general & internal medicine, NEUROPATHIES, biology, Guillain-Barre syndrome, business.industry, Guillain-Barré syndrome (GBS), treatment, course, Confounding, Immunoglobulins, Intravenous, Middle Aged, medicine.disease, Confidence interval, Psychiatry and Mental health, Treatment Outcome, biology.protein, Female, Surgery, Observational study, Neurology (clinical), Antibody, business, 030217 neurology & neurosurgery
Abstract: ObjectiveTo compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only.MethodsWe selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis.ResultsOf 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms.ConclusionIn patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.
Published: 2021

31. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: An international observational study

Author: Verboon, C, Harbo, T, Cornblath, D, Hughes, R, Van Doorn, P, Lunn, M, Gorson, K, Barroso, F, Kuwabara, S, Galassi, G, Lehmann, H, Kusunoki, S, Reisin, R, Binda, D, Cavaletti, G, Jacobs, B, Verboon C., Harbo T., Cornblath D. R., Hughes R. A. C., Van Doorn P. A., Lunn M. P., Gorson K. C., Barroso F., Kuwabara S., Galassi G., Lehmann H. C., Kusunoki S., Reisin R. C., Binda D., Cavaletti G., Jacobs B. C., Verboon, C, Harbo, T, Cornblath, D, Hughes, R, Van Doorn, P, Lunn, M, Gorson, K, Barroso, F, Kuwabara, S, Galassi, G, Lehmann, H, Kusunoki, S, Reisin, R, Binda, D, Cavaletti, G, Jacobs, B, Verboon C., Harbo T., Cornblath D. R., Hughes R. A. C., Van Doorn P. A., Lunn M. P., Gorson K. C., Barroso F., Kuwabara S., Galassi G., Lehmann H. C., Kusunoki S., Reisin R. C., Binda D., Cavaletti G., and Jacobs B. C.
Abstract: Objective: To compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only. Methods: We selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis. Results: Of 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms. Conclusion: In patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.
Published: 2021

32. Randomized trial of intravenous immunoglobulin maintenance treatment regimens in chronic inflammatory demyelinating polyradiculoneuropathy

Author: Apotheek Opleiding, Neurologen, Brain, Neurologie, MS VPG/Gynaecologie, Kuitwaard, K., Brusse, E., Jacobs, B. C., Vrancken, A. F.J.E., Eftimov, F., Notermans, N. C., van der Kooi, A. J., Fokkink, W. J.R., Nieboer, D., Lingsma, H. F., Merkies, I. S.J., van Doorn, P. A., Apotheek Opleiding, Neurologen, Brain, Neurologie, MS VPG/Gynaecologie, Kuitwaard, K., Brusse, E., Jacobs, B. C., Vrancken, A. F.J.E., Eftimov, F., Notermans, N. C., van der Kooi, A. J., Fokkink, W. J.R., Nieboer, D., Lingsma, H. F., Merkies, I. S.J., and van Doorn, P. A.
Published: 2021

33. Guillain-Barré Syndrome: Multifactorial Mechanisms versus Defined Subgroups

Author: Mech??, F. G. A. van der, Visser, L. H., Jacobs, B. C., Endtz, H. Ph., Meulstee, J., and van Doorn, P. A.
Published: 1997

34. Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study

Author: Verboon, C., Van Den Berg, B., Cornblath, D. R., Venema, E., Gorson, K. C., Lunn, M. P., Briani, C., Lingsma, H., Van Den Bergh, P., Harbo, T., Bateman, K., Pereon, Y., Sindrup, So. H., Kusunoki, S., Miller, J., Islam, Z., Hartung, H. -P., Chavada, G., Jacobs, B. C., Hughes, R. A. C., Van Doorn, P. A., UCL - SSS/IONS/NEUR - Clinical Neuroscience, and UCL - (SLuc) Service de neurologie
Subjects: second IVIg course, Poor prognosis, Treatment, treatment, hemic and lymphatic diseases, Guillain-Barré syndrome, poor prognosis, Second IVIg course
Abstract: OBJECTIVE: To compare disease course in patients with Guillain-Barré syndrome (GBS) with a poor prognosis who were treated with one or with two intravenous immunoglobulin (IVIg) courses. METHODS: From the International GBS Outcome Study, we selected patients whose modified Erasmus GBS Outcome Score at week 1 predicted a poor prognosis. We compared those treated with one IVIg course to those treated with two IVIg courses. The primary endpoint, the GBS disability scale at 4 weeks, was assessed with multivariable ordinal regression. RESULTS: Of 237 eligible patients, 199 patients received a single IVIg course. Twenty patients received an 'early' second IVIg course (1-2 weeks after start of the first IVIg course) and 18 patients a 'late' second IVIg course (2-4 weeks after start of IVIg). At baseline and 1 week, those receiving two IVIg courses were more disabled than those receiving one course. Compared with the one course group, the adjusted OR for a better GBS disability score at 4 weeks was 0.70 (95%CI 0.16 to 3.04) for the early group and 0.66 (95%CI 0.18 to 2.50) for the late group. The secondary endpoints were not in favour of a second IVIg course. CONCLUSIONS: This observational study did not show better outcomes after a second IVIg course in GBS with poor prognosis. The study was limited by small numbers and baseline imbalances. Lack of improvement was likely an incentive to start a second IVIg course. A prospective randomised trial is needed to evaluate whether a second IVIg course improves outcome in GBS.
Published: 2020

35. Siglec-7 specifically recognizes Campylobacter jejuni strains associated with oculomotor weakness in Guillain–Barré syndrome and Miller Fisher syndrome

Author: Heikema, A. P., Jacobs, B. C., Horst-Kreft, D., Huizinga, R., Kuijf, M. L., Endtz, H. P., Samsom, J. N., and van Wamel, W. J. B.
Published: 2013
Full Text: View/download PDF

36. Mannose-binding lectin polymorphisms are not associated with rheumatoid arthritis—confirmation in two large cohorts

Author: van de Geijn, F. E., Hazes, J. M. W., Geleijns, K., Emonts, M., Jacobs, B. C., den Goorbergh, B. C. M. Dufour-van, and Dolhain, R. J. E. M.
Published: 2008

37. Current treatment practice of Guillain-Barré syndrome

Author: Verboon C., Doets A. Y., Galassi G., Davidson A., Waheed W., Pereon Y., Shahrizaila N., Kusunoki S., Lehmann H. C., Harbo T., Monges S., Van Den Bergh P., Willison H. J., Cornblath D. R., Jacobs B. C., Hughes R. A. C., Gorson K. C., Hartung H. P., Van Doorn P. A., Van den Berg B., Roodbol J., Van Woerkom M., Reisin R. C., Reddel S. W., Islam Z., Islam B., Mohammad Q. D., Feasby T. E., Dardiotis E., Nobile-Orazio E., Bateman K., Illa I., Querol L., Hsieh S. T., Chavada G., Addington J. M., Ajroud-Driss S., Andersen H., Antonini G., Ariatti A., Attarian S., Badrising U. A., Barroso F. A., Benedetti L., Beronio A., Bianco M., Binda D., Briani C., Bunschoten C., Burmann J., Bella I. R., Bertorini T. E., Bhavaraju-Sanka R., Brannagan T. H., Busby M., Butterworth S., Casasnovas C., Cavaletti G., Chao C. C., Chen S., Chetty S., Claeys K. G., Conti M. E., Cosgrove J. S., Dalakas MC., Demichelis C., Derejko M. A., Dillmann U., Dimachkie M. M., Doppler K., Dornonville de la Cour C., Echaniz-Laguna A., Eftimov F., Faber C. G., Fazio R., Fokke C., Fujioka T., Fulgenzi E. A., Garcia-Sobrino T., Garssen M. P. J., Georgios H. M., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Giorli E., Goldstein J. M., Goyal N. A., Granit V., Grapperon A., Gutierrez G., Hadden R. D. M., Holbech J. V., Holt J. K. L., Pedret C. H., Htut M., Jellema K., Pascual I. J., Jimeno-Montero M. C., Kaida K., Karafiath S., Katzberg H. D., Kiers L., Kieseier B. C., Kimpinski K., Kleyweg R. P., Kokubun N., Kolb N. A., Kuitwaard K., Kuwabara S., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V., Ledingham D., Lucy S. T., Lunn M. P. T., Magot A., Manji H., Marchesoni C., Marfia G. A., Infante C. M., Hernandez E. M., Mataluni G., Mattiazi M., McDermott C. J., Meekins G. D., Miller J. A. L., Moris de la Tassa G., Physiotherapist J. M., Nascimbene C., Nowak R. J., Balaguer P. O., Osei-Bonsu M., Pan E. B. L., Pardal A. M., Pardo J., Pasnoor M., Pulley M., Rajabally Y. A., Rinaldi S., Ritter C., Roberts R. C., Rojas-Marcos I., Rudnicki S. A., Ruiz M., Sachs G. M., Samijn J. P. A., Santoro L., Savransky A., Schenone A., Schwindling L., Tous M. J. S., Sekiguchi Y., Sheikh K. A., Silvestri N. J., Sindrup S. H., Sommer C. L., Stein B., Stino A. M., Spyropoulos A., Srinivasan J., Styliani R., Suzuki H., Tankisi H., Tigner D., Twydell P., Van Damme P., Van der Kooi A. J., Van Dijk G. W., Van der Ree T., Van Koningsveld R., Valzania F., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Vytopil M. V., Wilken M., Wilkerson C., Wirtz P. W., Yamagishi Y., Zhou L., Zivkovic S. A., Neurology, AII - Infectious diseases, AII - Inflammatory diseases, ANS - Neuroinfection & -inflammation, Immunology, Erasmus MC other, UCL - SSS/IONS/NEUR - Clinical Neuroscience, UCL - (SLuc) Service de neurologie, Verboon, C, Doets, A, Galassi, G, Davidson, A, Waheed, W, Pereon, Y, Shahrizaila, N, Kusunoki, S, Lehmann, H, Harbo, T, Monges, S, Van Den Bergh, P, Willison, H, Cornblath, D, Jacobs, B, Hughes, R, Gorson, K, Hartung, H, Van Doorn, P, Van den Berg, B, Roodbol, J, Van Woerkom, M, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, Feasby, T, Dardiotis, E, Nobile-Orazio, E, Bateman, K, Illa, I, Querol, L, Hsieh, S, Chavada, G, Addington, J, Ajroud-Driss, S, Andersen, H, Antonini, G, Ariatti, A, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bunschoten, C, Burmann, J, Bella, I, Bertorini, T, Bhavaraju-Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Conti, M, Cosgrove, J, Dalakas, M, Demichelis, C, Derejko, M, Dillmann, U, Dimachkie, M, Doppler, K, Dornonville de la Cour, C, Echaniz-Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Garcia-Sobrino, T, Garssen, M, Georgios, H, Gijsbers, C, Gilchrist, J, Gilhuis, J, Giorli, E, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutierrez, G, Hadden, R, Holbech, J, Holt, J, Pedret, C, Htut, M, Jellema, K, Pascual, I, Jimeno-Montero, M, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Ledingham, D, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Infante, C, Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Moris de la Tassa, G, Physiotherapist, J, Nascimbene, C, Nowak, R, Balaguer, P, Osei-Bonsu, M, Pan, E, Pardal, A, Pardo, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas-Marcos, I, Rudnicki, S, Ruiz, M, Sachs, G, Samijn, J, Santoro, L, Savransky, A, Schenone, A, Schwindling, L, Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Styliani, R, Suzuki, H, Tankisi, H, Tigner, D, Twydell, P, Van Damme, P, Van der Kooi, A, Van Dijk, G, Van der Ree, T, Van Koningsveld, R, Valzania, F, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Zhou, L, and Zivkovic, S
Subjects: Adult, medicine.medical_specialty, Adolescent, Patient characteristics, PLASMA-EXCHANGE, 030204 cardiovascular system & hematology, Guillain-Barre Syndrome, Settore MED/26, Severity of Illness Index, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Severity of illness, Medicine, Effective treatment, INTRAVENOUS IMMUNOGLOBULIN, Humans, Prospective Studies, Child, Child, Preschool, Treatment Outcome, Prospective cohort study, Preschool, Guillain-Barre syndrome, business.industry, medicine.disease, RANDOMIZED-TRIAL, Prospective Studie, Hospital treatment, Treatment practice, Observational study, Neurology (clinical), business, 030217 neurology & neurosurgery, Human
Abstract: ObjectiveTo define the current treatment practice of Guillain-Barré syndrome (GBS).MethodsThe study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account.ResultsWe excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE.ConclusionsIn current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.
Published: 2019

38. Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain–Barré and reactive arthritis patients

Author: Ang, C. W., Krogfelt, K., Herbrink, P., Keijser, J., van Pelt, W., Dalby, T., Kuijf, M., Jacobs, B. C., Bergman, M. P., Schiellerup, P., and Visser, C. E.
Published: 2007

39. Amantadine for treatment of fatigue in Guillain-Barré syndrome: a randomised, double blind, placebo controlled, crossover trial

Author: Garssen, M P J, Schmitz, P I M, Merkies, I S J, Jacobs, B C, van der Meché, F G A, and van Doorn, P A
Published: 2006

40. Current treatment practice of Guillain-Barré syndrome

Author: Verboon, C, Doets, A, Galassi, G, Davidson, A, Waheed, W, Pereon, Y, Shahrizaila, N, Kusunoki, S, Lehmann, H, Harbo, T, Monges, S, Van Den Bergh, P, Willison, H, Cornblath, D, Jacobs, B, Hughes, R, Gorson, K, Hartung, H, Van Doorn, P, Van den Berg, B, Roodbol, J, Van Woerkom, M, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, Feasby, T, Dardiotis, E, Nobile-Orazio, E, Bateman, K, Illa, I, Querol, L, Hsieh, S, Chavada, G, Addington, J, Ajroud-Driss, S, Andersen, H, Antonini, G, Ariatti, A, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bunschoten, C, Burmann, J, Bella, I, Bertorini, T, Bhavaraju-Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Conti, M, Cosgrove, J, Dalakas, M, Demichelis, C, Derejko, M, Dillmann, U, Dimachkie, M, Doppler, K, Dornonville de la Cour, C, Echaniz-Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Garcia-Sobrino, T, Garssen, M, Georgios, H, Gijsbers, C, Gilchrist, J, Gilhuis, J, Giorli, E, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutierrez, G, Hadden, R, Holbech, J, Holt, J, Pedret, C, Htut, M, Jellema, K, Pascual, I, Jimeno-Montero, M, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Ledingham, D, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Infante, C, Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Moris de la Tassa, G, Physiotherapist, J, Nascimbene, C, Nowak, R, Balaguer, P, Osei-Bonsu, M, Pan, E, Pardal, A, Pardo, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas-Marcos, I, Rudnicki, S, Ruiz, M, Sachs, G, Samijn, J, Santoro, L, Savransky, A, Schenone, A, Schwindling, L, Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Styliani, R, Suzuki, H, Tankisi, H, Tigner, D, Twydell, P, Van Damme, P, Van der Kooi, A, Van Dijk, G, Van der Ree, T, Van Koningsveld, R, Valzania, F, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Zhou, L, Zivkovic, S, Verboon C., Doets A. Y., Galassi G., Davidson A., Waheed W., Pereon Y., Shahrizaila N., Kusunoki S., Lehmann H. C., Harbo T., Monges S., Van Den Bergh P., Willison H. J., Cornblath D. R., Jacobs B. C., Hughes R. A. C., Gorson K. C., Hartung H. P., Van Doorn P. A., Van den Berg B., Roodbol J., Van Woerkom M., Reisin R. C., Reddel S. W., Islam Z., Islam B., Mohammad Q. D., Feasby T. E., Dardiotis E., Nobile-Orazio E., Bateman K., Illa I., Querol L., Hsieh S. T., Chavada G., Addington J. M., Ajroud-Driss S., Andersen H., Antonini G., Ariatti A., Attarian S., Badrising U. A., Barroso F. A., Benedetti L., Beronio A., Bianco M., Binda D., Briani C., Bunschoten C., Burmann J., Bella I. R., Bertorini T. E., Bhavaraju-Sanka R., Brannagan T. H., Busby M., Butterworth S., Casasnovas C., Cavaletti G., Chao C. C., Chen S., Chetty S., Claeys K. G., Conti M. E., Cosgrove J. S., Dalakas MC., Demichelis C., Derejko M. A., Dillmann U., Dimachkie M. M., Doppler K., Dornonville de la Cour C., Echaniz-Laguna A., Eftimov F., Faber C. G., Fazio R., Fokke C., Fujioka T., Fulgenzi E. A., Garcia-Sobrino T., Garssen M. P. J., Georgios H. M., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Giorli E., Goldstein J. M., Goyal N. A., Granit V., Grapperon A., Gutierrez G., Hadden R. D. M., Holbech J. V., Holt J. K. L., Pedret C. H., Htut M., Jellema K., Pascual I. J., Jimeno-Montero M. C., Kaida K., Karafiath S., Katzberg H. D., Kiers L., Kieseier B. C., Kimpinski K., Kleyweg R. P., Kokubun N., Kolb N. A., Kuitwaard K., Kuwabara S., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V., Ledingham D., Lucy S. T., Lunn M. P. T., Magot A., Manji H., Marchesoni C., Marfia G. A., Infante C. M., Hernandez E. M., Mataluni G., Mattiazi M., McDermott C. J., Meekins G. D., Miller J. A. L., Moris de la Tassa G., Physiotherapist J. M., Nascimbene C., Nowak R. J., Balaguer P. O., Osei-Bonsu M., Pan E. B. L., Pardal A. M., Pardo J., Pasnoor M., Pulley M., Rajabally Y. A., Rinaldi S., Ritter C., Roberts R. C., Rojas-Marcos I., Rudnicki S. A., Ruiz M., Sachs G. M., Samijn J. P. A., Santoro L., Savransky A., Schenone A., Schwindling L., Tous M. J. S., Sekiguchi Y., Sheikh K. A., Silvestri N. J., Sindrup S. H., Sommer C. L., Stein B., Stino A. M., Spyropoulos A., Srinivasan J., Styliani R., Suzuki H., Tankisi H., Tigner D., Twydell P., Van Damme P., Van der Kooi A. J., Van Dijk G. W., Van der Ree T., Van Koningsveld R., Valzania F., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Vytopil M. V., Wilken M., Wilkerson C., Wirtz P. W., Yamagishi Y., Zhou L., Zivkovic S. A., Verboon, C, Doets, A, Galassi, G, Davidson, A, Waheed, W, Pereon, Y, Shahrizaila, N, Kusunoki, S, Lehmann, H, Harbo, T, Monges, S, Van Den Bergh, P, Willison, H, Cornblath, D, Jacobs, B, Hughes, R, Gorson, K, Hartung, H, Van Doorn, P, Van den Berg, B, Roodbol, J, Van Woerkom, M, Reisin, R, Reddel, S, Islam, Z, Islam, B, Mohammad, Q, Feasby, T, Dardiotis, E, Nobile-Orazio, E, Bateman, K, Illa, I, Querol, L, Hsieh, S, Chavada, G, Addington, J, Ajroud-Driss, S, Andersen, H, Antonini, G, Ariatti, A, Attarian, S, Badrising, U, Barroso, F, Benedetti, L, Beronio, A, Bianco, M, Binda, D, Briani, C, Bunschoten, C, Burmann, J, Bella, I, Bertorini, T, Bhavaraju-Sanka, R, Brannagan, T, Busby, M, Butterworth, S, Casasnovas, C, Cavaletti, G, Chao, C, Chen, S, Chetty, S, Claeys, K, Conti, M, Cosgrove, J, Dalakas, M, Demichelis, C, Derejko, M, Dillmann, U, Dimachkie, M, Doppler, K, Dornonville de la Cour, C, Echaniz-Laguna, A, Eftimov, F, Faber, C, Fazio, R, Fokke, C, Fujioka, T, Fulgenzi, E, Garcia-Sobrino, T, Garssen, M, Georgios, H, Gijsbers, C, Gilchrist, J, Gilhuis, J, Giorli, E, Goldstein, J, Goyal, N, Granit, V, Grapperon, A, Gutierrez, G, Hadden, R, Holbech, J, Holt, J, Pedret, C, Htut, M, Jellema, K, Pascual, I, Jimeno-Montero, M, Kaida, K, Karafiath, S, Katzberg, H, Kiers, L, Kieseier, B, Kimpinski, K, Kleyweg, R, Kokubun, N, Kolb, N, Kuitwaard, K, Kuwabara, S, Kwan, J, Ladha, S, Lassen, L, Lawson, V, Ledingham, D, Lucy, S, Lunn, M, Magot, A, Manji, H, Marchesoni, C, Marfia, G, Infante, C, Hernandez, E, Mataluni, G, Mattiazi, M, Mcdermott, C, Meekins, G, Miller, J, Moris de la Tassa, G, Physiotherapist, J, Nascimbene, C, Nowak, R, Balaguer, P, Osei-Bonsu, M, Pan, E, Pardal, A, Pardo, J, Pasnoor, M, Pulley, M, Rajabally, Y, Rinaldi, S, Ritter, C, Roberts, R, Rojas-Marcos, I, Rudnicki, S, Ruiz, M, Sachs, G, Samijn, J, Santoro, L, Savransky, A, Schenone, A, Schwindling, L, Tous, M, Sekiguchi, Y, Sheikh, K, Silvestri, N, Sindrup, S, Sommer, C, Stein, B, Stino, A, Spyropoulos, A, Srinivasan, J, Styliani, R, Suzuki, H, Tankisi, H, Tigner, D, Twydell, P, Van Damme, P, Van der Kooi, A, Van Dijk, G, Van der Ree, T, Van Koningsveld, R, Valzania, F, Varrato, J, Vermeij, F, Verschuuren, J, Visser, L, Vytopil, M, Wilken, M, Wilkerson, C, Wirtz, P, Yamagishi, Y, Zhou, L, Zivkovic, S, Verboon C., Doets A. Y., Galassi G., Davidson A., Waheed W., Pereon Y., Shahrizaila N., Kusunoki S., Lehmann H. C., Harbo T., Monges S., Van Den Bergh P., Willison H. J., Cornblath D. R., Jacobs B. C., Hughes R. A. C., Gorson K. C., Hartung H. P., Van Doorn P. A., Van den Berg B., Roodbol J., Van Woerkom M., Reisin R. C., Reddel S. W., Islam Z., Islam B., Mohammad Q. D., Feasby T. E., Dardiotis E., Nobile-Orazio E., Bateman K., Illa I., Querol L., Hsieh S. T., Chavada G., Addington J. M., Ajroud-Driss S., Andersen H., Antonini G., Ariatti A., Attarian S., Badrising U. A., Barroso F. A., Benedetti L., Beronio A., Bianco M., Binda D., Briani C., Bunschoten C., Burmann J., Bella I. R., Bertorini T. E., Bhavaraju-Sanka R., Brannagan T. H., Busby M., Butterworth S., Casasnovas C., Cavaletti G., Chao C. C., Chen S., Chetty S., Claeys K. G., Conti M. E., Cosgrove J. S., Dalakas MC., Demichelis C., Derejko M. A., Dillmann U., Dimachkie M. M., Doppler K., Dornonville de la Cour C., Echaniz-Laguna A., Eftimov F., Faber C. G., Fazio R., Fokke C., Fujioka T., Fulgenzi E. A., Garcia-Sobrino T., Garssen M. P. J., Georgios H. M., Gijsbers C. J., Gilchrist J. M., Gilhuis J., Giorli E., Goldstein J. M., Goyal N. A., Granit V., Grapperon A., Gutierrez G., Hadden R. D. M., Holbech J. V., Holt J. K. L., Pedret C. H., Htut M., Jellema K., Pascual I. J., Jimeno-Montero M. C., Kaida K., Karafiath S., Katzberg H. D., Kiers L., Kieseier B. C., Kimpinski K., Kleyweg R. P., Kokubun N., Kolb N. A., Kuitwaard K., Kuwabara S., Kwan J. Y., Ladha S. S., Lassen L. L., Lawson V., Ledingham D., Lucy S. T., Lunn M. P. T., Magot A., Manji H., Marchesoni C., Marfia G. A., Infante C. M., Hernandez E. M., Mataluni G., Mattiazi M., McDermott C. J., Meekins G. D., Miller J. A. L., Moris de la Tassa G., Physiotherapist J. M., Nascimbene C., Nowak R. J., Balaguer P. O., Osei-Bonsu M., Pan E. B. L., Pardal A. M., Pardo J., Pasnoor M., Pulley M., Rajabally Y. A., Rinaldi S., Ritter C., Roberts R. C., Rojas-Marcos I., Rudnicki S. A., Ruiz M., Sachs G. M., Samijn J. P. A., Santoro L., Savransky A., Schenone A., Schwindling L., Tous M. J. S., Sekiguchi Y., Sheikh K. A., Silvestri N. J., Sindrup S. H., Sommer C. L., Stein B., Stino A. M., Spyropoulos A., Srinivasan J., Styliani R., Suzuki H., Tankisi H., Tigner D., Twydell P., Van Damme P., Van der Kooi A. J., Van Dijk G. W., Van der Ree T., Van Koningsveld R., Valzania F., Varrato J. D., Vermeij F. H., Verschuuren J., Visser L. H., Vytopil M. V., Wilken M., Wilkerson C., Wirtz P. W., Yamagishi Y., Zhou L., and Zivkovic S. A.
Abstract: ObjectiveTo define the current treatment practice of Guillain-Barré syndrome (GBS).MethodsThe study was based on prospective observational data from the first 1,300 patients included in the International GBS Outcome Study. We described the treatment practice of GBS in general, and for (1) severe forms (unable to walk independently), (2) no recovery after initial treatment, (3) treatment-related fluctuations, (4) mild forms (able to walk independently), and (5) variant forms including Miller Fisher syndrome, taking patient characteristics and hospital type into account.ResultsWe excluded 88 (7%) patients because of missing data, protocol violation, or alternative diagnosis. Patients from Bangladesh (n = 189, 15%) were described separately because 83% were not treated. IV immunoglobulin (IVIg), plasma exchange (PE), or other immunotherapy was provided in 941 (92%) of the remaining 1,023 patients, including patients with severe GBS (724/743, 97%), mild GBS (126/168, 75%), Miller Fisher syndrome (53/70, 76%), and other variants (33/40, 83%). Of 235 (32%) patients who did not improve after their initial treatment, 82 (35%) received a second immune modulatory treatment. A treatment-related fluctuation was observed in 53 (5%) of 1,023 patients, of whom 36 (68%) were re-treated with IVIg or PE.ConclusionsIn current practice, patients with mild and variant forms of GBS, or with treatment-related fluctuations and treatment failures, are frequently treated, even in absence of trial data to support this choice. The variability in treatment practice can be explained in part by the lack of evidence and guidelines for effective treatment in these situations.
Published: 2019

41. Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands

Author: Koga, M, Ang, C W, Yuki, N, Jacobs, B C, Herbrink, P, van der Meché, F G A, Hirata, K, and van Doorn, P A
Published: 2001

42. Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barre syndrome

Author: Jacobs, B C, van Doorn, P A, Groeneveld, J H M, Tio-Gillen, A P, and van der Meche, F G A
Published: 1997

43. INTERNATIONAL GUILLAIN-BARRE SYNDROME OUTCOME STUDY (IGOS): DESCRIPTION OF THE FIRST 1000 PATIENTS

Author: van den Berg, Bu, Verboon, C., Doets, A., Chavada, G., Davidson, A., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H. P., Lehmann, H. C., Kusunoki, S., Querol, L., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., Mohammad, Deen Q., Van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S. T., Bateman, K., Dardiotis, E., Wang, Y., van Doorn, P. A., Hughes, R. A. C., Cornblath, D. R., Jacobs, B. C., van den Berg, Bu, Verboon, C., Doets, A., Chavada, G., Davidson, A., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H. P., Lehmann, H. C., Kusunoki, S., Querol, L., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., Mohammad, Deen Q., Van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S. T., Bateman, K., Dardiotis, E., Wang, Y., van Doorn, P. A., Hughes, R. A. C., Cornblath, D. R., and Jacobs, B. C.
Published: 2017

44. Campylobacter jejuni capsular genotypes are related to Guillain-Barré syndrome

Author: Heikema, A P, Islam, Z, Horst-Kreft, D, Huizinga, R, Jacobs, B C, Wagenaar, J A, Poly, F, Guerry, P, van Belkum, A, Parker, C T, Endtz, H P, Heikema, A P, Islam, Z, Horst-Kreft, D, Huizinga, R, Jacobs, B C, Wagenaar, J A, Poly, F, Guerry, P, van Belkum, A, Parker, C T, and Endtz, H P
Abstract: In about one in a thousand cases, a Campylobacter jejuni infection results in the severe polyneuropathy Guillain-Barré syndrome (GBS). It is established that sialylated lipo-oligosaccharides (LOS) of C. jejuni are a crucial virulence factor in GBS development. Frequent detection of C. jejuni with sialylated LOS in stools derived from patients with uncomplicated enteritis implies that additional bacterial factors should be involved. To assess whether the polysaccharide capsule is a marker for GBS, the capsular genotypes of two geographically distinct GBS-associated C. jejuni strain collections and an uncomplicated enteritis control collection were determined. Capsular genotyping of C. jejuni strains from the Netherlands revealed that three capsular genotypes, HS1/44c, HS2 and HS4c, were dominant in GBS-associated strains and capsular types HS1/44c and HS4c were significantly associated with GBS (p 0.05 and p 0.01, respectively) when compared with uncomplicated enteritis. In a GBS-associated strain collection from Bangladesh, capsular types HS23/36c, HS19 and HS41 were most prevalent and the capsular types HS19 and HS41 were associated with GBS (p 0.008 and p 0.02, respectively). Next, specific combinations of the LOS class and capsular genotypes were identified that were related to the occurrence of GBS. Multilocus sequence typing revealed restricted genetic diversity for strain populations with the capsular types HS2, HS19 and HS41. We conclude that capsular types HS1/44c, HS2, HS4c, HS19, HS23/36c and HS41 are markers for GBS. Besides a crucial role for sialylated LOS of C. jejuni in GBS pathogenesis, the identified capsules may contribute to GBS susceptibility.
Published: 2015

45. Campylobacter jejuni capsular genotypes are related to Guillain-Barré syndrome

Author: dI&I I&I-4, LS Klinisch Onderzoek Wagenaar, Infection & Immunity, Heikema, A P, Islam, Z, Horst-Kreft, D, Huizinga, R, Jacobs, B C, Wagenaar, J A, Poly, F, Guerry, P, van Belkum, A, Parker, C T, Endtz, H P, dI&I I&I-4, LS Klinisch Onderzoek Wagenaar, Infection & Immunity, Heikema, A P, Islam, Z, Horst-Kreft, D, Huizinga, R, Jacobs, B C, Wagenaar, J A, Poly, F, Guerry, P, van Belkum, A, Parker, C T, and Endtz, H P
Published: 2015

46. PROGRESS OF INTERNATIONAL GUILLAIN-BARRE STUDY (IGOS): A PROSPECTIVE STUDY ON CLINICAL AND BIOLOGICAL PREDICTORS OF DISEASE COURSE AND OUTCOME

Author: Verboon, C., van den Berg, B., Chavada, G., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H-P, Lehmann, H. C., Kusunoki, S., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., Mohammad, Q. D., van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S-T, Bateman, K., Dardiotis, E., van Doom, P. A., Hughes, R. A. C., Cornblath, D. R., Jacobs, B. C., Verboon, C., van den Berg, B., Chavada, G., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H-P, Lehmann, H. C., Kusunoki, S., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., Mohammad, Q. D., van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S-T, Bateman, K., Dardiotis, E., van Doom, P. A., Hughes, R. A. C., Cornblath, D. R., and Jacobs, B. C.
Published: 2015

47. Comparative population structure analysis of Campylobacter jejuni from human and poultry origin in Bangladesh

Author: Islam, Z, van Belkum, A, Wagenaar, Jaap, Cody, A J, de Boer, A G, Sarker, S K, Jacobs, B C, Talukder, K A, Endtz, H P, Islam, Z, van Belkum, A, Wagenaar, Jaap, Cody, A J, de Boer, A G, Sarker, S K, Jacobs, B C, Talukder, K A, and Endtz, H P
Abstract: Campylobacter jejuni is the most important cause of antecedent infections leading to Guillain-Barré syndrome (GBS) and Miller Fisher syndrome (MFS). The objective of the present study was to define the genetic diversity, population structure, and potential role of poultry in the transmission of Campylobacter to humans in Bangladesh. We determined the population structure of C. jejuni isolated from poultry (n = 66) and patients with enteritis (n = 39) or GBS (n = 10). Lipooligosaccharide (LOS) typing showed that 50/66 (76 %) C. jejuni strains isolated from poultry could be assigned to one of five LOS locus classes (A-E). The distribution of neuropathy-associated LOS locus classes A, B, and C were 30/50 (60 %) among the typable strains isolated from poultry. The LOS locus classes A, B, and C were significantly associated with GBS and enteritis-related C. jejuni strains more than for the poultry strains [(31/38 (82 %) vs. 30/50 (60 %), p < 0.05]. Multilocus sequence typing (MLST) defined 15 sequence types (STs) and six clonal complexes (CCs) among poultry isolates, including one ST-3740 not previously documented. The most commonly identified type, ST-5 (13/66), in chicken was seen only once among human isolates (1/49) (p < 0.001). Amplified fragment length polymorphism (AFLP) revealed three major clusters (A, B, and C) among C. jejuni isolated from humans and poultry. There seems to be a lack of overlap between the major human and chicken clones, which suggests that there may be additional sources for campylobacteriosis other than poultry in Bangladesh.
Published: 2014

48. Comparative population structure analysis of Campylobacter jejuni from human and poultry origin in Bangladesh

Author: LS Klinisch Onderzoek Wagenaar, I&I AVM, Advances in Veterinary Medicine, Islam, Z, van Belkum, A, Wagenaar, Jaap, Cody, A J, de Boer, A G, Sarker, S K, Jacobs, B C, Talukder, K A, Endtz, H P, LS Klinisch Onderzoek Wagenaar, I&I AVM, Advances in Veterinary Medicine, Islam, Z, van Belkum, A, Wagenaar, Jaap, Cody, A J, de Boer, A G, Sarker, S K, Jacobs, B C, Talukder, K A, and Endtz, H P
Published: 2014

49. PROGRESS OF INTERNATIONAL GUILLAIN-BARRE STUDY (IGOS): A PROSPECTIVE STUDY ON CLINICAL AND BIOLOGICAL PREDICTORS OF DISEASE COURSE AND OUTCOME

Author: Verboon, C., van den Berg, B., Chavada, G., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H-P, Lehmann, H. C., Kusunoki, S., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S-T, van Doorn, P. A., Hughes, R. A. C., Cornblath, D. R., Jacobs, B. C., Verboon, C., van den Berg, B., Chavada, G., Willison, H. J., Harbo, T., Gorson, K. C., Hartung, H-P, Lehmann, H. C., Kusunoki, S., Illa, I., Nobile-Orazio, E., Reisin, R. C., Reddel, S. W., Islam, Z., Islam, B., van den Bergh, P., Feasby, T. E., Pereon, Y., Shahrizaila, N., Hsieh, S-T, van Doorn, P. A., Hughes, R. A. C., Cornblath, D. R., and Jacobs, B. C.
Published: 2014

50. Quantum Logic Operations Using Single Photons and the Zeno Effect

Author: Franson, J. D., Jacobs, B. C., and Pittman, T. B.
Subjects: Condensed Matter::Quantum Gases, Quantum Physics, FOS: Physical sciences, Quantum Physics (quant-ph)
Abstract: We show that the quantum Zeno effect can be used to implement several quantum logic gates for photonic qubits, including a gate that is similar to the square-root of SWAP operation. The operation of these devices depends on the fact that photons can behave as if they were non-interacting fermions instead of bosons in the presence of a strong Zeno effect. These results are discussed within the context of several no-go theorems for non-interacting fermions or bosons., 15 pages, 4 figures
Published: 2004

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

121 results on '"Jacobs, B. C."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources